ReviewModulation of defensive behavior by periaqueductal gray NMDA/glycine-B receptor
-
Add time:09/27/2019 Source:sciencedirect.com
Glutamate (GLU) associated with glycine, act as co-transmitter at the N-methyl-d-aspartate/glycine-B (NMDA/GLYB) receptor. Dorsal periaqueductal gray (dPAG) neurons express NMDA/GLYB receptors suggesting a GLU physiological role in mediating the responses elicited by stimulation of this area. Immunohistochemical data provided evidence of a possible correlation among elevated plus-maze (EPM), fear-like defensive behavior, and dPAG activity. The present data show that whereas the NMDA/GLYB receptor agonists increased the open-arm avoidance responses in the EPM, the antagonists had the opposite effects. Microinjection of NMDA/GLYB receptor agonists within the dPAG during test sessions in the EPM resulted in an enduring learned fear response detected in the retest. Therefore, in addition to the proposed role for the dPAG in panic attacks (escape), these findings suggest that the dPAG can also participate in more subtle anxiety-like behaviors.
We also recommend Trading Suppliers and Manufacturers of N-(Methoxycarbonyl)glycine (cas 1670-97-9). Pls Click Website Link as below: cas 1670-97-9 suppliers
Prev:Research paperAn optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors
Next:Short communicationOne-pot synthesis of highly functionalized stable ketenimines of 2,2,2-trifluoro-N-aryl-acetamides) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research paperAn optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors09/26/2019
- Mini reviewAntagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions09/25/2019
- 6-Oxy-(N-succinimidyl acetate)-9-(2′-methoxycarbonyl)fluorescein as a new fluorescent labeling reagent for aliphatic amines in environmental and food samples using high-performance liquid chromatography09/24/2019
- Synthesis and structure activity relationships of glycine amide derivatives as novel Vascular Adhesion Protein-1 inhibitors09/10/2019


